This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Addex Therapeutics Ltd
Q12025
6/19/2025
Operator
Conference Operator
Hello, everyone.
Tim Dyer
Chief Executive Officer
I'd like to thank you all for attending our Q1 2025 financial results conference call. I'm here with Mikael Palinczeff, our head of Translational Finance, who will provide an update on our R&D program. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Nisha, who will review in more detail our NGR5 megabattleset modulator program for brain injury recovery, and I'll gather the popular modulations for clinical programs for COT. I will then review our Q1 2025 financial results followed.
Investor Relations
Call Moderator
With that, we will open the Q&A.
You're reading a preview of the ADXN Q1 2025 earnings call.
Free account.
Disclaimer